UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 8, 2018

 

 

Axovant Sciences Ltd.

(Exact Name of Registrant as specified in its charter)

 

 

Bermuda

 

001-37418

 

98-1333697

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

Suite 1, 3rd Floor

11-12 St. James’s Square

London SW1Y 4LB, United Kingdom

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: +44 203 318 9708

 

Not Applicable

(Registrant’s name or former address, if change since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 


 

Item 8.01.                                        Other Events.

 

On January 8, 2018, Axovant Sciences Ltd. issued a press release announcing results from its Phase 2b HEADWAY study of intepirdine in patients with dementia with Lewy bodies (DLB), its pilot Phase 2 study of intepirdine in patients with dementia with gait impairment, and its pilot Phase 2 study of nelotanserin in patients with DLB and Parkinson’s disease dementia who experience visual hallucinations. Based on the totality of intepirdine data to date, the intepirdine program will be discontinued and the Company plans to explore a larger nelotanserin DLB study focused on motor function and psychosis.

 

A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

 

Item 9.01.

 

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press Release of Axovant Sciences Ltd., dated January 8, 2018

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Axovant Sciences Ltd.

 

 

 

 

 

 

By:

/s/ David Hung, M.D.

 

Name:

David Hung, M.D.

 

Title:

Principal Executive Officer

 

 

 

 

Date:  January 8, 2018

 

 

3